Prevention and therapy of organovascular arterial ischaemic disease

Czech version

Authors: P. Gavornik; A. Dukát; Ľ. Gašpar; M. Kováčová; A. Uhrinová; M. Šulanová; G. Gubová; K. Letková
Authors‘ workplace: Vedúci lekár: doc. MUDr. Peter Gavorník, Ph. D., mim. prof. ; Prednosta: prof. MUDr. Andrej Dukát, CSc., FESC., EFIM Hon., FACP Hon., FRSP (London) ; Prvé angiologické pracovisko (PAP) ; II. interná klinika LFUK a UNB, Bratislava, Slovenská republika
Published in: Prakt. Lék. 2010; 90(12): 708-714
Category: Reviews

Overview

Organovascular arterial ischemic diseases (cardiovascular, cerebrovascular, extremitovascular, renovascular, pulmovascular, intestinovascular, oculovascular, otovascular and others) are important manifestations of systemic atherosclerosis and other arterial diseases of the vascular system (arteriolosclerosis; diabetic macroangiopathy; diabetic microangiopathy; Mönckeberg’s mediosclerosis; arteritis – vasculitis; syndromes of arterial compression; fibromuscular dysplasia; cystic adventitial degeneration; arterial thrombosis; arterial embolism; traumatic and posttraumatic arteriopathies; physical arteriopathies; chemical and toxic arteriopathies; iatrogenic arterial occlusions; dissection of aorta and of arteries; complicated arterial aneurysms; arteriovenous fistula etc.).

Effective prevention and treatment of organovascular diseases is discussed in this article.

Key words:
arteries, organovascular ischemic diseases, prevention, treatment, nondrug therapy, drug therapy.

Sources

1. Abramson, B.L., Huckell, V., Anand, S. et al. Canadian Cardiovascular Society Consensus Conference: Peripheral arterial disease- Executive summary. Can. J. Cardiol. 2005, 21, p. 997-1006.

2. ACCORD Lipid Study brings new hope to people with type 2 diabetes and atherogenic dyslipidemia says international academic foundation [on-line]. Dostupné na www:http://www.multivu.prnewswire.com/mnr/r3i/42622/.

3. Antithrombotic and thrombolytic therapy: American College of Chest Physicians (ACCP) evidence-based clinical practice guidelines (8th edition). Chest 2008, 133, (6 Suppl), p. 67S-968S.

4. Bada, V. Výživa ako prevencia kardiovaskulárnych chorôb. Kardiológia pre prax 2009, 7,(2),s. 91-96.

5. Brunzell, J.D., Davidson, M., Furberg, C.D. et al. Lipoprotein Management in Patients With Cardiometabolic Risk – Consensus Conference Report From The American Diabetes Association and the American College of Cardiology Foundation. JACC 2008, 51 (15), p. 1512-1524.

6. Burt, R.K., Testori, A., Oyama, Y. et al. Autologous peripheral blood CD133+ cell implantation for limb salvage in patients with critical limb ischemia. Bone Marrow Transplantation 2010, 45,(1), p. 111-116.

7. Cambou, J.P., Aboyans, V., Constans, J. et al. Characteristics and outcome of patients hospitalised for lower extremity peripheral artery disease in France: the COPART Registry. Eur. J. Vasc. Endovasc. Surg. 2010, 39(5), p. 577-785.

8. Coppola, G., Romano, G., Corrado, E. et al. Peripheral artery disease: potential role of ACE-inhibitor therapy. Vasc. Health Risk. Manag. 2008, 4(6), p. 1179-1187.

9. Dosluoglu, H.H., Lall, P., Nader, N.D. et al. Insulin use is associated with poor limb salvage and survival in diabetic patients with chronic limb ischemia. J. Vasc. Surg. 2010, 51(5), p. 1178-1189.

10. Dukát, A. Reziduálne kardiovaskulárne riziko – závažný problém, ktorý si bude vyžadovať nové liečebné prístupy. Cardiol. 2008, 17(6), s. 229-233.

11. Frouchart, J.C., Sacks, F.M., Hermans, M.P. et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidemic patients. Am. J. Cardiol. 2008, 102 (10 Suppl), p. 1K-34K.

12. Gavorník P. Všeobecná angiológia. Angiologická propedeutika. Cievne choroby. 2. Vyd. Bratislava: Univerzita Komenského – Vydavateľstvo UK, 2001, 268 s.

13. Gavorník, P., Holomáň, M., Kolesár, J. et al. Kinezioterapia ischemickej choroby dolných končatín u chorých po rekonštrukčnej operácii tepien. Čas. Lék. čes. 1986, 125(32), s. 1000-1003.

14. Gavorník, P., Kolesár, J., Dukát, A. Pohybová liečba (kinezioterapia) ischemickej choroby dolných končatín III. štádia. Vnitř. Lék. 1986, 32(6), s. 597-604.

15. Gavorník, P., Kolesár, P., Hudec, I. et al. Význam kinezioterapie ischemickej choroby dolných končatín u chorých s rodinnými hyperlipoproteinémiami. Vnitř. Lék. 1981, 27(1), s. 72-79.

16. Gavorník, P. Etiopatogenéza neurovaskulárnych ischemických chorôb (syndrómov). Neurológia 2010, 5(2), s. 61-68

17. Gavorník, P. Angiológia. 1. Vyd. Bratislava: Univerzita Komenského - Vydavateľstvo UK, 1998, 148 s.

18. Gavorník, P. Artériotromboprofylaxia v klinickej praxi. Cardiol. 2010, 19 (4), s. 293-299.

19. Gavorník, P. Ateroskleróza a iné choroby tepien. 1. Vyd. Bratislava: Univerzita Komenského - Vydavateľstvo UK, 1999, 216 s.

20. Gavorník, P. Cievne choroby. In: Klimo, F. a kol.: Praktické a rodinné lekárstvo. 1. Vyd. Senica: Vydavateľstvo Prognóza, 1999. 1100 (382 – 400).

21. Gavorník, P. Choroby tepien. In: Ďuriš, I., Hulín, I., Bernadič, M. (eds.): Princípy internej medicíny. Slovac Academic Press. Bratislava 2001. s. 784 – 797.

22. Gavorník, P. Končatinovocievne ischemické choroby. B 2.1/1-92. In: Gavorník, P., Hrubiško, M., Rozborilová, E. (eds). Diferenciálna diagnostika kardiovaskulárnych, respiračných a hematologických ochorení I. 1. Vyd. Bratislava: Dr. Josef Raabe, 2010. 300. ISBN 978-80-89182-46-6

23. Gavorník P. Obliterujúce choroby artérií a končatinovocievna ischemická choroba. Nová klinicko-etiologicko-anatomicko-patofyziologická klasifikácia. Cardiol. Sk. 2010, 19(3), s. 201-213.

24. Graham, I., Atar, D., Borch-Johnsen, K. et al. European guidelines on cardiovascular disease prevention in clinical practice: Executive summary. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. (Constituted by representatives of nine societies and by invited experts). Eur. Heart J. 2007, 28(19), p. 2375 – 2414.

25. Hiatt, W.R. Medical treatment of peripheral arterial disease and claudication. New Engl. J. Med. 2001, 344(21), p. 1608-1620.

26. Hirsch, A.T., Haskal, Z.J., Hertzer, N.R. et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus and Vascular Disease Foundation. Circulation 2006, 113(11), e463-e654.

27. Horie, T., Onodera, R., Akamastu, M. et al. Japan Study Group of Peripheral Vascular Regeneration Cell Therapy (JPRCT). Long-term clinical outcomes for patients with lower limb ischemia implanted with G-CSF-mobilized autologous peripheral blood mononuclear cells. Atherosclerosis 2010, 208(2), p. 461-466.

28. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines – Endorsed by the National Heart, Lung, and Blood Institute, American College of Cardiology Foundation, and American Heart Association. Circulation 2004, 110, p. 227-239.

29. Kawamoto, A., Katayama, M., Handa, N. et al. Intramuscular transplantation of G-CSF-mobilized CD34(+) cells in patients with critical limb ischemia: a phase I/Iia, multicenter, single-blinded, dose-escalation clinical trial. Stem Cells. 2009, 27(11), p. 2857-2864.

30. Kiernan, T.J., Hynes, B.G., Ruggiero, N.J. et al. Comprehensive evaluation and medical management of infrainguinal peripheral artery disease: „when to treat, when not to treat“. Techn. Vasc. Intervent. Radiol. 2010, 13(1), p. 2-10.

31. Lara-Hernandez, R., Lozano-Vilardell, P., Blanes, P. et al. Safety and efficacy of therapeutic angiogenesis as a novel treatment in patients with critical limb ischemia. Ann. Vasc. Surg. 2010, 24(2), p. 287-294.

32. Lawall, H., Gorriahn, H., Amendt, K. et al. Long-term outcomes after medical and interventional therapy of critical limb ischemia. Eur. J. Intern. Med. 2009, 20(6), p. 616-621.

33. Napoli, C., Farzati, B., Sica, V. et al. Beneficial effects of autologous bone marrow cell infusion and antioxidants/L-arginine in patients with chronic critical limb ischemia. Eur. J. Cardiovasc. Prevent. Rehab. 2008, 15(6), p. 709-718.

34. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III. Final Report. Circulation 2002, 106, p. 3143-3421.

35. Norgren, L., Hiatt, W.R., Dormandy, J.A. et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur. J. Vasc. Endovasc. Surg. 2007; 33(Suppl 1), p. S1-S75.

36. Payvandi, L., Dyer, A., McPherson, D. et al. Physical activity during daily life and brachial artery flow-mediated dilation in peripheral arterial disease. Vascular. Medicine 2009, 14(3), p 193-201.

37. Pecka, M., Malý, J. Metabolické a aktivačné děje v krevních deštičkách a možnosti jejich inhibice. Vnitř. Lék. 2009, 55(3), s. 263-266.

38. Perry, C. Extended-Release Niacin (Nicotinic Acid/Laropiprant). Drugs 2009, 69, p. 1-15.

39. Remková, A. Aktuálne otázky antidoštičkovej liečby kyselinou acetylsalicylovou v primárnej a sekundárnej prevencii cievnych ochorení u diabetikov. Interná med. 2007, 7(1), s. 36-39.

40. Residual Risk Reduction Initiative [on-line]. Dostupné na www: www.r3i.org.

41. Šefránek, V (ed.). Ochorenia končatinových tepien a ich chirurgická liečba. Bratislava: SAP 2001, 240 s.

42. Šimko, F., Pechanová, O. Remodelling of the Heart and Vessels in experimental hypertension: advances in protection. J. Hypertens. 2010, 28, (Suppl. 1), p. S1-S6.

43. Štvrtinová, V., Šefránek, V., Murín, J. a kol. Odporúčania pre diagnostiku a liečbu periférneho artériového ochorenia končatín. Odporúčania Slovenskej angiologickej spoločnosti, Slovenskej spoločnosti pre cievnu chirurgiu, Slovenskej kardiologickej spoločnosti, Slovenskej internistickej spoločnosti a Slovenskej rádiologickej spoločnosti. Cardiol. 2006, 15(6), s. 317–323.

44. TASC – Management of peripheral arterial disease. TransAtlantic Inter-Society Consensus (TASC). Int. Angiol. 2000, 19 (Suppl. 1), p. 1-310.

45. The seventh American College of Chest Physicians (ACCP) conference on antithrombotic and thrombolytic therapy. From evidence to application. Chest 2004, 126, (3 Suppl), p. 1S-696S.

46. Tomečko, M., Petrášová, D., Frankovičová, M. Moderné trendy v liečbe ischemickej choroby dolnej končatiny. Ateroskleróza 2010, 14, (1-2), s. 53-58.

47. VAS (Vascular Independent Research and Education European Organization) [on-line]. Dostupné na www: http://www.vas-int.org.